MCID: RRC011
MIFTS: 37

Rare Cancer of Corpus Uteri

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Rare Cancer of Corpus Uteri

MalaCards integrated aliases for Rare Cancer of Corpus Uteri:

Name: Rare Cancer of Corpus Uteri 59
Rare Malignant Tumor of Corpus Uteri 59

Classifications:



External Ids:

UMLS via Orphanet 73 C0153574
Orphanet 59 ORPHA213569

Summaries for Rare Cancer of Corpus Uteri

MalaCards based summary : Rare Cancer of Corpus Uteri, also known as rare malignant tumor of corpus uteri, is related to prostate transitional cell carcinoma and malignant spiradenoma. An important gene associated with Rare Cancer of Corpus Uteri is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are RET signaling and Signaling by GPCR. Related phenotypes are Decreased viability and Decreased viability

Related Diseases for Rare Cancer of Corpus Uteri

Diseases related to Rare Cancer of Corpus Uteri via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 174)
# Related Disease Score Top Affiliating Genes
1 prostate transitional cell carcinoma 10.6 PIK3CA CTNNB1
2 malignant spiradenoma 10.6 TP53 PIK3CA
3 nevus of ota 10.6 TP53 BRAF
4 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
5 bladder squamous cell carcinoma 10.5 TP53 BRAF
6 papillary craniopharyngioma 10.5 CTNNB1 BRAF
7 prostate adenoid cystic carcinoma 10.5 PIK3CA HRAS
8 pleomorphic adenoma carcinoma 10.5 TP53 ERBB2
9 bent bone dysplasia syndrome 10.5 FGFR2 ERBB2
10 gallbladder adenoma 10.5 HRAS CTNNB1
11 adult hepatocellular carcinoma 10.5 TP53 PIK3CA CTNNB1
12 non-proliferative fibrocystic change of the breast 10.5 TP53 ERBB2
13 urachal adenocarcinoma 10.4 KRAS BRAF
14 sigmoid neoplasm 10.4 KRAS HRAS
15 ethmoid sinus adenocarcinoma 10.4 PIK3CA HRAS
16 splenic diffuse red pulp small b-cell lymphoma 10.4 TP53 MAP2K1
17 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
18 dermatosis papulosa nigra 10.4 PIK3CA MTOR
19 ethmoid sinus cancer 10.4 PIK3CA HRAS
20 breast squamous cell carcinoma 10.4 TP53 PIK3CA ERBB2
21 mutyh-associated polyposis 10.4 TP53 KRAS
22 brain stem glioma 10.4 TP53 PIK3CA BRAF
23 large intestine adenocarcinoma 10.4 MTOR CTNNB1
24 periampullary adenoma 10.3 KRAS HRAS
25 stomach disease 10.3 TP53 ERBB2 CTNNB1
26 pancreatic neuroendocrine tumor 10.3 PIK3CA MTOR
27 breast ductal carcinoma 10.3 TP53 ERBB2 CTNNB1
28 rare adenocarcinoma of the breast 10.3 TP53 PIK3CA KRAS
29 spitz nevus 10.3 TP53 HRAS BRAF
30 skin squamous cell carcinoma 10.3 TP53 PIK3CA HRAS
31 colonic benign neoplasm 10.3 KRAS CTNNB1 BRAF
32 hyperplastic polyposis syndrome 10.3 TP53 KRAS BRAF
33 mature teratoma 10.3 TP53 KRAS BRAF
34 adenosquamous carcinoma 10.3 TP53 PIK3CA KRAS
35 melanomatosis 10.3 NRAS HRAS
36 bile duct cysts 10.2 KRAS HRAS
37 apocrine adenoma 10.2 PIK3CA KRAS HRAS
38 giant congenital nevus 10.2 NRAS HRAS
39 aggressive digital papillary adenocarcinoma 10.2 PIK3CA KRAS HRAS
40 barrett's adenocarcinoma 10.2 TP53 KRAS ERBB2
41 hemimegalencephaly 10.2 PIK3CA MTOR CTNNB1
42 lung adenoid cystic carcinoma 10.2 PIK3CA KRAS HRAS
43 anal squamous cell carcinoma 10.2 TP53 PIK3CA
44 female reproductive endometrioid cancer 10.2 TP53 PTEN CTNNB1
45 familial adenomatous polyposis 10.2 TP53 KRAS CTNNB1
46 bladder adenocarcinoma 10.2 HRAS CTNNB1
47 nasal cavity adenocarcinoma 10.2 TP53 KRAS HRAS
48 synchronous bilateral breast carcinoma 10.2 TP53 PTEN
49 biliary papillomatosis 10.2 TP53 KRAS HRAS
50 appendix disease 10.2 KRAS HRAS

Graphical network of the top 20 diseases related to Rare Cancer of Corpus Uteri:



Diseases related to Rare Cancer of Corpus Uteri

Symptoms & Phenotypes for Rare Cancer of Corpus Uteri

GenomeRNAi Phenotypes related to Rare Cancer of Corpus Uteri according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.04 MTOR HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 11.04 KRAS
3 Decreased viability GR00107-A-1 11.04 MAP2K1
4 Decreased viability GR00221-A-1 11.04 MTOR HRAS NRAS KRAS PIK3CA
5 Decreased viability GR00221-A-2 11.04 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-3 11.04 MAP2K1 ERBB2 HRAS NRAS
7 Decreased viability GR00221-A-4 11.04 MTOR ERBB2 PIK3CA BRAF
8 Decreased viability GR00301-A 11.04 FGFR2 KRAS BRAF
9 Decreased viability GR00342-S-1 11.04 FGFR2 MAP2K1 MTOR
10 Decreased viability GR00342-S-2 11.04 FGFR2 MAP2K1 MTOR
11 Decreased viability GR00342-S-3 11.04 FGFR2 MAP2K1
12 Decreased viability GR00381-A-1 11.04 KRAS BRAF
13 Decreased viability GR00402-S-2 11.04 FGFR2 MAP2K1 MTOR ERBB2 HRAS NRAS
14 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.97 CTNNB1 ERBB2 FGFR2 HRAS MTOR NRAS
15 Decreased cell migration GR00055-A-1 9.88 BRAF CTNNB1 HRAS KRAS MTOR PIK3CA
16 Decreased viability in esophageal squamous lineage GR00235-A 9.86 BRAF CTNNB1 ERBB2 HRAS KRAS PIK3CA
17 Increased cell death HMECs cells GR00103-A-0 9.55 CTNNB1 PIK3CA PPP2R1A PTEN TP53
18 Increased cell migration GR00055-A-3 9.43 BRAF CTNNB1 HRAS KRAS MTOR PIK3CA
19 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KRAS MTOR NRAS PPP2R1A

MGI Mouse Phenotypes related to Rare Cancer of Corpus Uteri:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
2 cardiovascular system MP:0005385 10.41 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
3 growth/size/body region MP:0005378 10.4 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
4 endocrine/exocrine gland MP:0005379 10.38 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
5 homeostasis/metabolism MP:0005376 10.38 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
6 cellular MP:0005384 10.36 BRAF CTNNB1 ERBB2 FGFR2 KRAS MAP2K1
7 embryo MP:0005380 10.35 BRAF CTNNB1 ERBB2 FGFR2 KRAS MAP2K1
8 mortality/aging MP:0010768 10.32 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
9 digestive/alimentary MP:0005381 10.31 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
10 integument MP:0010771 10.29 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
11 craniofacial MP:0005382 10.27 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
12 neoplasm MP:0002006 10.26 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
13 immune system MP:0005387 10.21 BRAF CTNNB1 FGFR2 KRAS MTOR NRAS
14 nervous system MP:0003631 10.2 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
15 hematopoietic system MP:0005397 10.18 BRAF CTNNB1 FGFR2 KRAS MTOR NRAS
16 normal MP:0002873 10.18 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
17 muscle MP:0005369 10.15 BRAF CTNNB1 ERBB2 FGFR2 KRAS MTOR
18 limbs/digits/tail MP:0005371 10.14 BRAF CTNNB1 ERBB2 FGFR2 KRAS NRAS
19 adipose tissue MP:0005375 10.11 BRAF FGFR2 MTOR PIK3CA PTEN TP53
20 liver/biliary system MP:0005370 10.07 BRAF CTNNB1 FGFR2 KRAS NRAS PTEN
21 hearing/vestibular/ear MP:0005377 10.06 BRAF CTNNB1 FGFR2 KRAS MAP2K1 TP53
22 no phenotypic analysis MP:0003012 10.03 CTNNB1 FGFR2 HRAS KRAS MTOR NRAS
23 renal/urinary system MP:0005367 9.92 BRAF CTNNB1 FGFR2 HRAS KRAS MTOR
24 pigmentation MP:0001186 9.91 BRAF CTNNB1 FGFR2 KRAS NRAS PTEN
25 reproductive system MP:0005389 9.91 BRAF CTNNB1 ERBB2 FGFR2 KRAS MAP2K1
26 respiratory system MP:0005388 9.81 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
27 skeleton MP:0005390 9.73 BRAF CTNNB1 ERBB2 FGFR2 HRAS KRAS
28 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR2 KRAS MAP2K1 NRAS

Drugs & Therapeutics for Rare Cancer of Corpus Uteri

Search Clinical Trials , NIH Clinical Center for Rare Cancer of Corpus Uteri

Genetic Tests for Rare Cancer of Corpus Uteri

Anatomical Context for Rare Cancer of Corpus Uteri

Publications for Rare Cancer of Corpus Uteri

Variations for Rare Cancer of Corpus Uteri

ClinVar genetic disease variations for Rare Cancer of Corpus Uteri:

6 (show top 50) (show all 287)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
3 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
4 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
5 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
6 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
7 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
8 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
9 MAP2K1 NM_002755.3(MAP2K1): c.370C> T (p.Pro124Ser) single nucleotide variant Pathogenic rs1057519732 15:66729162-66729162 15:66436824-66436824
10 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
11 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
12 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
13 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
15 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
16 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
17 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
18 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
19 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
20 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
21 PIK3CA NM_006218.4(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic rs121913272 3:178927980-178927980 3:179210192-179210192
22 NRAS NM_002524.5(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
23 NRAS NM_002524.5(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
24 NRAS NM_002524.5(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
25 NRAS NM_002524.5(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
26 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
27 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
28 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
29 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
30 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
31 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
32 NRAS NM_002524.5(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913250 1:115258748-115258748 1:114716127-114716127
33 PPP2R1A NM_014225.6(PPP2R1A): c.536C> T (p.Pro179Leu) single nucleotide variant Pathogenic rs786205228 19:52715971-52715971 19:52212718-52212718
34 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
35 NRAS NM_002524.5(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs121913237 1:115258747-115258747 1:114716126-114716126
36 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
37 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
38 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
39 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
40 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
41 FGFR2 NM_000141.4(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 10:123279677-123279677 10:121520163-121520163
42 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
43 BRAF NM_004333.6(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 7:140453133-140453133 7:140753333-140753333
44 CTNNB1 NM_001904.4(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 3:41266097-41266097 3:41224606-41224606
45 CTNNB1 NM_001904.4(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 3:41266113-41266113 3:41224622-41224622
46 CTNNB1 NM_001904.4(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 3:41266098-41266098 3:41224607-41224607
47 CTNNB1 NM_001904.4(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 3:41266101-41266101 3:41224610-41224610
48 CTNNB1 NM_001904.4(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 3:41266136-41266136 3:41224645-41224645
49 CTNNB1 NM_001904.4(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 3:41266137-41266137 3:41224646-41224646
50 CTNNB1 NM_001904.4(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 3:41266125-41266125 3:41224634-41224634

Expression for Rare Cancer of Corpus Uteri

Search GEO for disease gene expression data for Rare Cancer of Corpus Uteri.

Pathways for Rare Cancer of Corpus Uteri

Pathways related to Rare Cancer of Corpus Uteri according to GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.71 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
2
Show member pathways
14.26 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
3
Show member pathways
14.13 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
4
Show member pathways
13.98 TP53 PTEN PPP2R1A NRAS MAP2K1 KRAS
5
Show member pathways
13.98 TP53 PTEN PPP2R1A NRAS MTOR MAP2K1
6
Show member pathways
13.86 PPP2R1A PIK3CA NRAS MTOR MAP2K1 KRAS
7
Show member pathways
13.83 TP53 PPP2R1A NRAS MAP2K1 KRAS HRAS
8
Show member pathways
13.82 TP53 PPP2R1A NRAS MTOR MAP2K1 KRAS
9
Show member pathways
13.7 NRAS MTOR MAP2K1 KRAS HRAS FGFR2
10
Show member pathways
13.69 TP53 PPP2R1A PIK3CA NRAS MTOR MAP2K1
11
Show member pathways
13.66 PPP2R1A PIK3CA NRAS MAP2K1 KRAS HRAS
12
Show member pathways
13.62 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
13
Show member pathways
13.57 TP53 PTEN PPP2R1A NRAS MTOR KRAS
14
Show member pathways
13.54 PTEN PIK3CA NRAS MAP2K1 KRAS HRAS
15
Show member pathways
13.53 TP53 PPP2R1A PIK3CA NRAS MAP2K1 KRAS
16
Show member pathways
13.46 PPP2R1A NRAS MAP2K1 KRAS HRAS FGFR2
17
Show member pathways
13.44 PTEN NRAS MAP2K1 KRAS HRAS FGFR2
18
Show member pathways
13.43 PTEN NRAS KRAS HRAS FGFR2 ERBB2
19
Show member pathways
13.39 TP53 PTEN NRAS MTOR MAP2K1 KRAS
20
Show member pathways
13.38 TP53 PPP2R1A PIK3CA NRAS KRAS HRAS
21
Show member pathways
13.26 TP53 PTEN NRAS MTOR MAP2K1 KRAS
22
Show member pathways
13.22 PPP2R1A NRAS MTOR MAP2K1 KRAS HRAS
23
Show member pathways
13.18 TP53 NRAS MAP2K1 KRAS HRAS CTNNB1
24
Show member pathways
13.17 PPP2R1A PIK3CA NRAS MAP2K1 KRAS HRAS
25
Show member pathways
13.16 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
26
Show member pathways
13.16 TP53 PTEN PIK3CA NRAS MTOR MAP2K1
27
Show member pathways
13.15 TP53 PTEN PIK3CA NRAS MTOR MAP2K1
28
Show member pathways
13.13 PTEN PPP2R1A NRAS MAP2K1 KRAS HRAS
29
Show member pathways
13.11 PTEN PIK3CA NRAS MTOR MAP2K1 KRAS
30
Show member pathways
13.1 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
31
Show member pathways
13.1 PTEN PIK3CA NRAS MAP2K1 KRAS HRAS
32
Show member pathways
13.07 PTEN PIK3CA NRAS MTOR MAP2K1 KRAS
33
Show member pathways
13.04 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
34
Show member pathways
13.02 PPP2R1A NRAS MTOR MAP2K1 KRAS HRAS
35
Show member pathways
13 TP53 NRAS MAP2K1 KRAS HRAS
36
Show member pathways
12.99 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
37
Show member pathways
12.98 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
38
Show member pathways
12.98 PTEN PIK3CA MTOR MAP2K1 KRAS HRAS
39 12.98 TP53 NRAS MAP2K1 KRAS HRAS FGFR2
40
Show member pathways
12.96 PIK3CA NRAS KRAS HRAS FGFR2
41
Show member pathways
12.95 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR2
42
Show member pathways
12.91 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
43
Show member pathways
12.9 TP53 PPP2R1A NRAS MAP2K1 KRAS HRAS
44
Show member pathways
12.89 PTEN PIK3CA NRAS MTOR MAP2K1 KRAS
45
Show member pathways
12.87 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR
46 12.85 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR2
47
Show member pathways
12.82 TP53 PIK3CA NRAS KRAS HRAS ERBB2
48
Show member pathways
12.81 NRAS MAP2K1 KRAS HRAS BRAF
49
Show member pathways
12.81 PPP2R1A PIK3CA NRAS KRAS HRAS FGFR2
50
Show member pathways
12.8 TP53 PIK3CA NRAS MTOR MAP2K1 KRAS

GO Terms for Rare Cancer of Corpus Uteri

Cellular components related to Rare Cancer of Corpus Uteri according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.85 TP53 PTEN PPP2R1A PIK3CA MTOR MAP2K1
2 mitochondrion GO:0005739 9.8 TP53 PTEN PPP2R1A MTOR MAP2K1 KRAS
3 plasma membrane GO:0005886 9.7 PTEN PPP2R1A PIK3CA NRAS MAP2K1 KRAS
4 PML body GO:0016605 9.54 TP53 PTEN MTOR
5 postsynaptic cytosol GO:0099524 9.4 PTEN MTOR
6 cytoplasm GO:0005737 9.4 TP53 PTEN PPP2R1A PIK3CA MTOR MAP2K1
7 membrane GO:0016020 10.1 TP53 PPP2R1A PIK3CA NRAS MTOR MAP2K1

Biological processes related to Rare Cancer of Corpus Uteri according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 TP53 PTEN MAP2K1 HRAS CTNNB1
2 phosphorylation GO:0016310 9.95 PIK3CA MTOR MAP2K1 FGFR2 ERBB2 BRAF
3 heart development GO:0007507 9.92 PTEN MAP2K1 ERBB2 CTNNB1
4 positive regulation of protein phosphorylation GO:0001934 9.88 MTOR KRAS HRAS ERBB2
5 protein phosphorylation GO:0006468 9.88 PIK3CA MTOR MAP2K1 FGFR2 ERBB2 BRAF
6 T cell receptor signaling pathway GO:0050852 9.87 PIK3CA HRAS BRAF
7 peptidyl-tyrosine phosphorylation GO:0018108 9.87 MAP2K1 FGFR2 ERBB2 BRAF
8 cellular response to hypoxia GO:0071456 9.86 TP53 PTEN MTOR
9 animal organ morphogenesis GO:0009887 9.86 HRAS FGFR2 BRAF
10 positive regulation of protein kinase B signaling GO:0051897 9.85 PIK3CA MTOR FGFR2 ERBB2
11 wound healing GO:0042060 9.83 MTOR FGFR2 ERBB2
12 negative regulation of neuron apoptotic process GO:0043524 9.81 PIK3CA KRAS HRAS BRAF
13 cell cycle arrest GO:0007050 9.8 TP53 MTOR MAP2K1 HRAS
14 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.79 NRAS KRAS HRAS
15 positive regulation of MAP kinase activity GO:0043406 9.78 KRAS HRAS ERBB2
16 positive regulation of epithelial cell proliferation GO:0050679 9.77 HRAS FGFR2 ERBB2
17 visual learning GO:0008542 9.77 MTOR KRAS BRAF
18 positive regulation of MAPK cascade GO:0043410 9.76 HRAS FGFR2 ERBB2 CTNNB1
19 thymus development GO:0048538 9.73 MAP2K1 CTNNB1 BRAF
20 face development GO:0060324 9.7 MAP2K1 BRAF
21 cardiac muscle tissue development GO:0048738 9.7 PTEN MTOR
22 regulation of myelination GO:0031641 9.7 MTOR CTNNB1
23 cell proliferation GO:0008283 9.7 TP53 PTEN CTNNB1
24 epithelial tube branching involved in lung morphogenesis GO:0060441 9.69 KRAS CTNNB1
25 regulation of osteoclast differentiation GO:0045670 9.68 MTOR CTNNB1
26 regulation of synaptic transmission, GABAergic GO:0032228 9.68 PTEN KRAS
27 regulation of osteoblast differentiation GO:0045667 9.67 FGFR2 CTNNB1
28 negative regulation of macroautophagy GO:0016242 9.67 PIK3CA MTOR
29 morphogenesis of embryonic epithelium GO:0016331 9.67 FGFR2 CTNNB1
30 negative regulation of apoptotic process GO:0043066 9.67 TP53 PTEN CTNNB1 BRAF
31 anoikis GO:0043276 9.65 PIK3CA MTOR
32 negative regulation of cell size GO:0045792 9.65 PTEN MTOR
33 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.64 TP53 MAP2K1
34 lung-associated mesenchyme development GO:0060484 9.64 FGFR2 CTNNB1
35 response to isolation stress GO:0035900 9.63 KRAS HRAS
36 Ras protein signal transduction GO:0007265 9.62 TP53 NRAS KRAS HRAS
37 trachea formation GO:0060440 9.61 MAP2K1 CTNNB1
38 cell aging GO:0007569 9.61 TP53 MTOR HRAS
39 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 PTEN MAP2K1 HRAS FGFR2 BRAF
40 mesenchymal cell proliferation involved in lung development GO:0060916 9.54 FGFR2 CTNNB1
41 MAPK cascade GO:0000165 9.5 NRAS MAP2K1 KRAS HRAS FGFR2 ERBB2
42 regulation of axon regeneration GO:0048679 9.43 PTEN MAP2K1 BRAF
43 phosphatidylinositol phosphorylation GO:0046854 9.38 PIK3CA
44 positive regulation of transcription by RNA polymerase III GO:0045945 9.35 MTOR
45 positive regulation of gene expression GO:0010628 9.28 TP53 PTEN MTOR MAP2K1 KRAS HRAS
46 apoptotic process GO:0006915 10.06 TP53 PTEN PPP2R1A HRAS FGFR2
47 positive regulation of cell proliferation GO:0008284 10.03 PTEN KRAS HRAS FGFR2 CTNNB1

Molecular functions related to Rare Cancer of Corpus Uteri according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.91 TP53 PIK3CA MTOR MAP2K1 FGFR2 ERBB2
2 protein kinase activity GO:0004672 9.83 MTOR MAP2K1 FGFR2 ERBB2 BRAF
3 protein serine/threonine kinase activity GO:0004674 9.8 PIK3CA MTOR MAP2K1 BRAF
4 protein heterodimerization activity GO:0046982 9.8 TP53 PPP2R1A ERBB2 CTNNB1 BRAF
5 protein phosphatase binding GO:0019903 9.65 TP53 ERBB2 CTNNB1
6 protein C-terminus binding GO:0008022 9.56 MAP2K1 HRAS ERBB2 CTNNB1
7 protein tyrosine kinase activity GO:0004713 9.46 MAP2K1 FGFR2 ERBB2 BRAF
8 kinase activity GO:0016301 9.43 PIK3CA MTOR MAP2K1 FGFR2 ERBB2 BRAF
9 nucleotide binding GO:0000166 9.23 NRAS MTOR MAP2K1 KRAS HRAS FGFR2
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.16 PIK3CA
11 protein binding GO:0005515 10.13 TP53 PTEN PPP2R1A PIK3CA NRAS MTOR

Sources for Rare Cancer of Corpus Uteri

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....